Cinnarizine

Overview

Cinnarizine is an orally active, effective and selective inhibitor of L-type calcium channel Cav1.3 with an IC 50 of 1.5 μM (in vestibular hair cells). Cinnarizine can cross the blood-brain barrier and regulate calcium homeostasis and dopamine neurotransmission. Cinnarizine inhibits the influx of calcium ions into smooth muscle cells by blocking L-type calcium channels, thereby relaxing vascular smooth muscle, improving cerebral circulation and reducing blood viscosity, while antagonizing dopamine receptors. Cinnarizine can be used in the study of vestibular vertigo, Meniere's disease and cerebrovascular diseases.

Application

Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Cardiovascular Disease | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Parkinson's Disease | Products > Disease Areas > Hypertension | Products > Disease Areas > Obesity | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Signaling Pathways > Neuronal Signaling | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > GPCR/G Protein | Products > Research Areas > Endocrinology | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > Calcium Channel | Products > Signaling Pathways > Histamine Receptor

Product Information

• Catalog No.: HY-B1090
• CAS No.: 298-57-7
• Molecular Formula: C26H28N2
• Molecular Weight: 368.51
• Purity: 99.56%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 0.71 mg/mL (1.93 mM); Clear solution
• Availability: In-stock

Source

Original product source